United Therapeutics is a profitable rare-disease biotech with an unusually strong cash baseline. The hard question is not whether the company currently earns money; it is whether pulmonary hypertension concentration, lifecycle management and pipeline investment can keep compounding without a product-cycle break.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
